Stereotaxis (NYSEAMERICAN:STXS) Shares Down 5.3% – Should You Sell?

Stereotaxis Inc. (NYSEAMERICAN:STXS)’s stock price traded down 5.3% during mid-day trading on Friday . The stock traded as low as $1.77 and last traded at $1.78. 590,981 shares changed hands during mid-day trading, an increase of 57% from the average session volume of 375,655 shares. The stock had previously closed at $1.88.

Analysts Set New Price Targets

Several analysts have issued reports on the company. Citigroup restated a “market outperform” rating on shares of Stereotaxis in a research note on Wednesday. Piper Sandler restated an “overweight” rating and issued a $3.50 price objective (down from $4.00) on shares of Stereotaxis in a research note on Wednesday, May 13th. Four equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $3.88.

Stereotaxis Stock Down 5.3%

The company has a market cap of $173.98 million, a P/E ratio of -7.42 and a beta of 1.35. The stock has a 50 day moving average price of $1.90 and a two-hundred day moving average price of $2.14.

Stereotaxis (NYSEAMERICAN:STXS) last announced its earnings results on Monday, March 9th. The company reported ($0.06) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.06). The company had revenue of $8.64 million for the quarter, compared to analyst estimates of $9.24 million. Stereotaxis had a negative return on equity of 163.30% and a negative net margin of 69.50%. Equities analysts anticipate that Stereotaxis Inc. will post -0.2 EPS for the current year.

Hedge Funds Weigh In On Stereotaxis

Large investors have recently made changes to their positions in the company. WealthPLAN Partners LLC acquired a new stake in Stereotaxis during the fourth quarter worth approximately $29,000. SG Americas Securities LLC acquired a new stake in Stereotaxis during the fourth quarter worth approximately $33,000. BNP Paribas Financial Markets grew its position in Stereotaxis by 106.5% during the third quarter. BNP Paribas Financial Markets now owns 11,461 shares of the company’s stock worth $36,000 after buying an additional 5,910 shares in the last quarter. Schonfeld Strategic Advisors LLC acquired a new stake in Stereotaxis during the third quarter worth approximately $38,000. Finally, HRT Financial LP acquired a new stake in Stereotaxis during the fourth quarter worth approximately $42,000. Institutional investors own 45.35% of the company’s stock.

Stereotaxis Company Profile

Stereotaxis, Inc is a medical device company that develops and commercializes robotic magnetic navigation systems for use in electrophysiology procedures. Its core technology leverages precisely controlled magnetic fields to guide ultra-thin, magnetically enabled catheters through the vascular system, allowing physicians to perform complex cardiac ablation and diagnostic procedures with enhanced precision and stability. This platform aims to reduce procedure times and radiation exposure for both patients and clinical staff.

The company’s flagship offering, the Niobe Magnetic Navigation System, integrates with a variety of catheter types and electrophysiology mapping systems to support treatment of arrhythmias such as atrial fibrillation and ventricular tachycardia.